Cure in metastatic breast cancer

被引:26
作者
Westphal T. [1 ,2 ,4 ]
Gampenrieder S.P. [1 ,2 ,4 ]
Rinnerthaler G. [1 ,2 ,4 ]
Greil R. [1 ,2 ,3 ,4 ]
机构
[1] IIIrd Medical Department with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Müllner Hauptstraße 48, Salzburg
[2] Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Salzburg
[3] Cancer Cluster Salzburg, Salzburg
[4] Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT), Vienna
关键词
Chemotherapy; Immunotherapy; Oligometastatic; Surgery; Targeted therapy;
D O I
10.1007/s12254-018-0426-9
中图分类号
学科分类号
摘要
Oligometastatic disease characterizes a distinct subgroup of metastatic breast cancer patients that might benefit from different treatment strategies to achieve long-lasting remission and potentially cure. Those long-lasting remissions are reported after locoregional treatment of the primary tumor and all metastatic sites in several case series; however, unlike other tumor entities, prospective data are lacking. Furthermore, tumor eradication by excellent systemic anticancer therapy with novel chemotherapies and targeted agents can lead to long-term survival. In addition, reactivation of the host immune defense by immuno-oncologic drugs can achieve long-lasting tumor control. So far, unfortunately, checkpoint inhibitors as monotherapy have led to responses only in a small percentage of patients with metastatic breast cancer. This short review summarizes available data on long-lasting remissions and potential cure in metastatic breast cancers. It describes and discusses data on locoregional treatment, chemo-, antibody- and immunotherapy and tries to select individual patients for whom a multidisciplinary treatment approach with curative intention might be an option to achieve long-term survival. © 2018, The Author(s).
引用
收藏
页码:172 / 179
页数:7
相关论文
共 50 条
  • [31] Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer
    Sivapiragasam, Abirami
    Kumar, Prashanth Ashok
    Sokol, Ethan S.
    Albacker, Lee A.
    Killian, Jonathan K.
    Ramkissoon, Shakti H.
    Huang, Richard S. P.
    Severson, Eric A.
    Brown, Charlotte A.
    Danziger, Natalie
    McGregor, Kimberly
    Ross, Jeffrey S.
    CANCER MEDICINE, 2021, 10 (01): : 53 - 61
  • [32] Emerging therapeutic targets in metastatic progression: A focus on breast cancer
    Li, Zhuo
    Kang, Yibin
    PHARMACOLOGY & THERAPEUTICS, 2016, 161 : 79 - 96
  • [33] Advancing Immunotherapy in Metastatic Breast Cancer
    Mariam Mansour
    Zhi Ling Teo
    Stephen J. Luen
    Sherene Loi
    Current Treatment Options in Oncology, 2017, 18
  • [34] Emerging drugs in metastatic breast cancer
    Dizdar, Omer
    Altundag, Kadri
    EXPERT OPINION ON EMERGING DRUGS, 2009, 14 (01) : 85 - 98
  • [35] Management of metastatic breast cancer (MBC)
    Al-Amri, Ali M.
    LIFE SCIENCE JOURNAL-ACTA ZHENGZHOU UNIVERSITY OVERSEAS EDITION, 2012, 9 (04): : 597 - 601
  • [36] Personalized medicine for metastatic breast cancer
    Chen, Tom Wei-Wu
    Bedard, Philippe L.
    ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 (01): : 52 - 62
  • [37] Advancing Immunotherapy in Metastatic Breast Cancer
    Mansour, Mariam
    Teo, Zhi Ling
    Luen, Stephen J.
    Loi, Sherene
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (06)
  • [38] Systemic chemotherapy for metastatic breast cancer
    Yannan Zhao
    Biyun Wang
    OncologyandTranslationalMedicine, 2015, 1 (05) : 226 - 232
  • [39] Therapeutic options for metastatic breast cancer
    Morris, Patrick G.
    McArthur, Heather L.
    Hudis, Clifford A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (06) : 967 - 981
  • [40] Bevacizumab in the treatment of metastatic breast cancer
    Schuetz, Florian
    Sohn, Christof
    Schneeweiss, Andreas
    BREAST CARE, 2007, 2 (02) : 82 - 88